Shares in Catalent (NYSE:CTLT) rose yesterday after the drug-delivery company met expectations on Wall Street with its fiscal 1st-quarter results.
The Somerset, N.J.-based company posted profits of $4.6 million, or 4¢ per share, on sales of $442.2 million for the 3 months ended Sept. 30, for a bottom-line slide of -60.7% on sales growth of 4.5% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Catalent tops Q1 estimates, profits fall 61% appeared first on MassDevice.